Episode

BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.

Podcast
Business Of Biotech
Published
Jul 6, 2026
Duration seconds
2347
Processing state
not_requested
Canonical source
https://www.buzzsprout.com/1011661/episodes/19430442-bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d.mp3
Audio
https://www.buzzsprout.com/1011661/episodes/19430442-bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d.mp3
JSON
/v1/public/podcasts/business-of-biotech-123501/episodes/bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d
Markdown
/podcast/business-of-biotech-123501/bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/business-of-biotech-123501/bob-bio-biotech-investing-and-deals-with-sofinnova-s-maha-radhakrishnan-m-d.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

We love to hear from our listeners. Send us a message. This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic in...